The discovery of nalidixic acid is one pinnacle in medicinal chemistry, which opened a new
area of research that has led to the discovery of several life-saving antimicrobial agents …

More than two decades have elapsed since the publication of the first genome sequence of
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …

Tuberculosis is a global health dilemma. In 2016, the WHO reported 10.4 million incidences
and 1.7 million deaths. The need to develop new treatments for those infected with …

Tuberculosis now ranks as the leading cause of death in the world due to a single infectious
agent. Current standard of care treatment can achieve very high cure rates for drug-sensitive …

Mycobacterium tuberculosis cytochrome bd quinol oxidase (cyt bd), the alternative terminal
oxidase of the respiratory chain, has been identified as playing a key role during chronic …

Development of novel anti-tuberculosis combination regimens that increase efficacy and
reduce treatment timelines will improve patient compliance, limit side-effects, reduce costs …

Tuberculosis (TB) has been considered as the highly chronic, contagious and infectious
disorder caused by Mycobacterium tuberculosis (Mtb). Every year more than 10 million …

Worldwide control of the tuberculosis (TB) epidemic has not been achieved, and the latest
statistics show that the TB problem might be more endemic than previously thought …

It is critical that novel classes of antituberculosis drugs are developed to combat the
increasing burden of infections by multidrug-resistant strains. To identify such a novel class …

Mycobacterium tuberculosis (Mtb) exhibits remarkable metabolic flexibility that enables it to
survive a plethora of host environments during its life cycle. With the advent of bedaquiline …